KalVista Pharmaceuticals, Inc. Board of Directors

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Dr. Christopher M. Yea Ph.D.

Dr. Christopher M. Yea Ph.D.

Chief Development Officer

Jarrod Aldom

Jarrod Aldom

Vice President of Corporate Communications

Ms. Rachel M. Morten

Ms. Rachel M. Morten

Senior Vice President of Regulatory Affairs & QA

Mr. Ryan Baker

Mr. Ryan Baker

Head of Investor Relations

Dr. Michael D. Smith Pharm.D.

Dr. Michael D. Smith Pharm.D.

Senior Vice President of Development

Ms. Nicole Sweeny

Ms. Nicole Sweeny

Chief Commercial Officer

Mr. Brian Piekos

Mr. Brian Piekos

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.